Navigation Links
Biotica Strikes Significant Collaboration Deal With GlaxoSmithKline
Date:1/12/2009

CAMBRIDGE, England, January 12 /PRNewswire/ -- Biotica Technology Limited, a privately-held biotechnology company, announces a significant Collaboration and License Agreement with GlaxoSmithKline to discover, develop and commercialise novel erythromycin-based macrolides in inflammatory diseases.

In a three year research collaboration, Biotica will use its bioengineering technology to produce compounds that are not readily accessible via conventional medicinal chemistry approaches. GSK will apply its expertise in macrolide drug discovery to optimize further the properties of candidate drugs, and will have responsibility for development and commercialisation.

Under the terms of the agreement, Biotica receives an initial cash payment, and is eligible to receive up to GBP86 million per compound in success-based development, approval and commercialisation milestone payments, as well as tiered royalties on net sales of resulting products. In addition, GSK has made an up front equity investment in a first close of Biotica's Series D financing. The Series D round remains open for additional investors and will support progression of the company's high-value, unpartnered programs.

"The deal with GSK significantly boosts our cash position and enables us to further strengthen our position as the leading natural product optimization company. We look forward to working with GSK to exploit the significant potential of macrolides in inflammatory diseases," said Dr. Edward Hodgkin, CEO of Biotica.

"Biotica's technology and expertise enables discovery of new medicines which could not be made by conventional means" said Dr. Ming Zhang, Biotica's Senior Vice President of R&D. "We had demonstrated our capacity for optimizing macrolides in a successful pilot study conducted prior to completion of the agreement" he added.

About Biotica

Biotica is a privately-held biotechnology company with a growing pipeline of novel therapeutic programmes supported by clinical validation. Biotica's programmes include rapamycin-based mTOR inhibitors (partnered with Wyeth), novel FK506 analogues for inhaled use in asthma, cyclophilin inhibitors and erythromycin macrolides (in collaboration with GlaxoSmithKline). All of Biotica's projects employ its proprietary technology, polyketide bioengineering, which enables it to select from the many known polyketides with biological activity and make a range of derivatives that are either difficult or impossible to make by medicinal chemistry methods. For additional information visit http://www.biotica.com

    Enquiries

    Biotica Technology Ltd       Tel: +44-1799-532920
    Dr Edward E. Hodgkin, CEO
    enquiries@biotica.com

    Financial Dynamics           Tel: +44(0)20-7831-3113
    Ben Atwell
    Ben.Atwell@fd.com



'/>"/>
SOURCE Biotica Technology Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
2. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
3. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
4. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
5. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
6. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
7. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
8. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
9. DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study
10. FASgen Announces Significant Milestone in Its Cancer Drug Development Program
11. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... , Jan 23, 2017 Research and Markets ... Analysis & Trends - Product - Forecast to 2025" report to ... Report Highlights: ... and future market trends to identify the investment opportunities ... Key market trends across the business segments, Regions and ...
(Date:1/23/2017)... -- Stock-Callers.com today presents the following Generic Drugs ... ), Sophiris Bio Inc. (NASDAQ: SPHS ), Momenta ... Inc. (NASDAQ: AGRX ). These companies are part ... trade on Friday, January 20 th , 2017, with the ... health care companies in the S&P 500 also were sinking ...
(Date:1/23/2017)... , 23. Januar 2017  ResMed (NYSE: ... ) und 3B Medical ( Winter Haven, Florida ... eine Vereinbarung über die Beilegung aller globalen Rechtsstreitigkeiten zwischen ... der Verkauf ihrer bestehenden Produkte im Tausch gegen ... Zahlung an 3B leisten, um das in ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... , ... "ProRandom is a set of camera tools that allow video editors to integrate up ... X," said Christina Austin - CEO of Pixel Film Studios. , With ProRandom, video ... footage. ProRandom works by using a virtual camera to create the illusion of a ...
(Date:1/23/2017)... , ... January 23, 2017 , ... ... high-quality general gynecological care and gynecological services for women of all ... care for a wide variety of reproductive services from routine health screenings to ...
(Date:1/23/2017)... ... January 23, 2017 , ... The ... at seafoodnutrition.org/programs and seafoodnutrition.org/resources to assist in teaching communities and individuals about ... been developed for use by nutrition educators and influencers within the public ...
(Date:1/23/2017)... ... January 23, 2017 , ... Valentine’s Day is a time when many people celebrate ... For those who may be looking for the ideal present, Atlanta-based Perimeter Plastic Surgery ... an additional $25 free. Or, spend $200 and get $50 free. , “A lot ...
(Date:1/22/2017)... Viejo, California (PRWEB) , ... January 22, 2017 , ... ... Photo Cloud to create a beautiful 3D slideshow with complete ease," said Christina Austin ... the Generators browser to place in the FCPX timeline. Presets include scenes ...
Breaking Medicine News(10 mins):